✨ Medicinal Product Notices
4 JULY
NEW ZEALAND GAZETTE
2025
Product:
PEG-Intron
Active Ingredient:
Peginterferon alfa-2b 80µg
Dosage Form:
Powder for injection
New Zealand Sponsor:
Schering-Plough Pty imited
Manufacturer:
Schering-Plough Company, Brinny, Innishannon, County Cork, Ireland
Product:
Tractocile
Active Ingredient:
Atosiban acetate 7.95mg/mL equivalent to Atosiban 7.5 mg/mL
Dosage Form:
Concentrate for injection
New Zealand Sponsor:
Pharmaco (NZ) Limited
Manufacturer:
Ferring AB, Limhamn, Sweden
Dated this 1st day of July 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go4482
Renewal of Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product:
Synercid
Active Ingredients:
Dalfopristin 350mg
Quinupristin 150mg
Dosage Form:
Powder for infusion
New Zealand Sponsor:
Aventis Pharma Limited
Manufacturer:
Catalytica Pharmaceuticals Inc, Greenville, North Carolina, United States of America
Note: This consent is valid for 2 years from 20 June 2002.
Dated this 2nd day of July 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go4484
Consent to the Distribution of a Changed Medicine
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicine which was referred to the Minister of Health under the provisions of section 24 (5) of the Act and is set out in the Schedule hereto:
Schedule
Product:
Caelyx
Active Ingredient:
Doxorubicin hydrochloride 2mg/mL
Dosage Form:
Concentrate for infusion
New Zealand Sponsor:
Schering-Plough Pty Limited
Manufacturer:
Ben Venue Laboratories Inc, Bedford, Ohio, United States of America
Dated this 2nd day of July 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go4483
Internal Affairs
Films, Videos, and Publications Classification Act 1993
Revocation of Interim Restriction Order
Pursuant to section 51 (2) of the Films, Videos, and Publications Classification Act 1993, the President of the Film and Literature Board of Review hereby revokes the following interim restriction order:
“An interim restriction order made in respect to the film or video Visitor Q on 11 April 2002, is revoked by the President of the Film and Literature Board of Review, on her own motion. The order of revocation is made to assist parties making submissions to the board, to make application to the Office of Film and Literature Classification, pursuant to section 44 of the Films, Videos, and Publications Classification Act 1993, to view Visitor Q in preparation for their appearance before the board on 18 July should they so wish.”
Dated at Rotorua this 28th day of June 2002.
CLAUDIA ELLIOTT, President, Film and Literature Board of Review.
go4436
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2002, No 76
Gazette.govt.nz —
NZ Gazette 2002, No 76
✨ LLM interpretation of page content
🏥
Medicinal Product Details
(continued from previous page)
🏥 Health & Social Welfare1 July 2002
Medicines, Pharmaceuticals, PEG-Intron, Tractocile
- G. R. Boyd, Chief Advisor, Safety and Regulation
🏥 Renewal of Provisional Consent to the Distribution of a New Medicine
🏥 Health & Social Welfare2 July 2002
Medicines, Pharmaceuticals, Synercid
- G. R. Boyd, Chief Advisor, Safety and Regulation
🏥 Consent to the Distribution of a Changed Medicine
🏥 Health & Social Welfare2 July 2002
Medicines, Pharmaceuticals, Caelyx
- G. R. Boyd, Chief Advisor, Safety and Regulation
⚖️ Revocation of Interim Restriction Order
⚖️ Justice & Law Enforcement28 June 2002
Films, Videos, Publications, Classification, Visitor Q
- Claudia Elliott, President, Film and Literature Board of Review